论文部分内容阅读
目的探讨对2型糖尿病肾病患者实施相关临床指标进行检测的效果与临床意义。方法方便收集50例2型糖尿病肾病患者的临床资料予以回顾性分析研究,资料收集时间为2015年1月—2016年12月。将这50例患者设为实验组,另从同期在该院接受体检的人群中随机选择50名设为健康对照组。于清晨空腹状态下采集两组研究对象的静脉血,检测同型半胱氨酸以及胱抑素C水平。另收集两组的中段晨尿送检,采用免疫散射比浊法检测α_1-微球蛋白水平。结果两组研究对象在平均年龄以及平均体质量等方面情况基本相同,各项临床指标经比较差异无统计学意义(P>0.05)。对两组研究对象的α_1-微球蛋白、同型半胱氨酸和胱抑素C水平进行检测,记录检测结果并进行组间统计学比较可得,实验组检测水平分别为(19.85±5.02)mg/L、(15.78±3.12)μmol/L、(1.51±0.45)mg/L,均显著高于对照组的(3.75±1.27)mg/L、(9.12±2.35)μmol/L、(0.62±0.21)mg/L(P<0.05)。结论对2型糖尿病肾病患者的血清中α_1-微球蛋白、同型半胱氨酸和胱抑素C指标进行检测可较为直观的了解到患者的肾脏功能损伤情况,为临床诊治提供一定的参考依据。
Objective To explore the effect and clinical significance of detecting related clinical indexes in patients with type 2 diabetic nephropathy. Methods The clinical data of 50 patients with type 2 diabetic nephropathy were collected retrospectively. The data collection period was from January 2015 to December 2016. The 50 patients were set as the experimental group, another from the same period in the hospital for medical examination in the crowd randomly selected 50 as a healthy control group. Venous blood was collected from both groups in the morning fasting state to detect homocysteine and cystatin C levels. The other two groups were collected in the middle of morning urine examination, the use of immune nephelometry α_1-microglobulin levels. Results The two groups were basically the same in terms of average age and average body weight. There was no significant difference in clinical indexes between the two groups (P> 0.05). The levels of α 1 -microglobulin, homocysteine and cystatin C in two groups of subjects were detected, the test results were recorded and compared statistically between groups, the test group were (19.85 ± 5.02) (3.75 ± 1.27) mg / L, (9.12 ± 2.35) μmol / L, (0.62 ± 2.35) μmol / L, (15.78 ± 3.12) μmol / L and 0.21) mg / L (P <0.05). Conclusions The serum levels of α 1-microglobulin, homocysteine and cystatin C in patients with type 2 diabetic nephropathy can be more intuitively understood in patients with renal impairment and provide some reference for clinical diagnosis and treatment .